Neurological disorders

Teva Presents New Data at 7th European Academy of Neurology Congress Suggesting Socio-Economic Factors May Contribute to the Significant Under-Diagnosis of Migraine

Retrieved on: 
Monday, June 21, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Migraine, Headaches, Branches of biology, Nervous system, Medicine, Neurological disorders, Channelopathies, Rare diseases, Migraine-associated vertigo, Messoud Ashina, the Epidemiological Study, the ‘Beyond Migraine: The Real You survey, Teva, THE EPIDEMIOLOGICAL STUDY, THE ‘BEYOND MIGRAINE: THE REAL YOU SURVEY, TEVA

A retrospective study of migraine epidemiology in Southern Israel, supported by Teva and presented at the virtual 7th Congress of the European Academy of Neurology (EAN), found extreme variability in the prevalence of diagnosed patients with migraine across the geographic area studied.

Key Points: 
  • A retrospective study of migraine epidemiology in Southern Israel, supported by Teva and presented at the virtual 7th Congress of the European Academy of Neurology (EAN), found extreme variability in the prevalence of diagnosed patients with migraine across the geographic area studied.
  • Migraine is a difficult, challenging neurological disease which does not discriminate dependent on an individuals social status.
  • We believe migraine should be prioritised as a highly prevalent and often under-looked neurological disorder.
  • A 2020 Teva-sponsored research project, Beyond Migraine: The Real You, surveyed over 7,500 people living with the disease in 10 European countries.

H1 2021 Neuromyelitis Optica (Devic's Syndrome) Global Clinical Trials Review - ResearchAndMarkets.com

Retrieved on: 
Friday, June 18, 2021
Biotechnology, Other Health, Health, Pharmaceutical, Clinical trials, Neurological disorders, Health sciences, Health, Autoimmune diseases, Devic, Central nervous system disorders, Clinical trial, Neuromyelitis optica spectrum disorder, Myelitis, NMO

The "Neuromyelitis Optica (Devic's Syndrome) - Global Clinical Trials Review, H1, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Neuromyelitis Optica (Devic's Syndrome) - Global Clinical Trials Review, H1, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This report provides an overview of Neuromyelitis Optica (Devic's Syndrome) Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Neuromyelitis Optica (Devic's Syndrome) .
  • Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe.

Scholar Rock to Present Apitegromab TOPAZ Phase 2 Trial Results Highlighting Pharmacokinetic (PK) and Pharmacodynamic (PD) Data at the 2021 European Academy of Neurology Congress

Retrieved on: 
Friday, June 18, 2021
Health, Other Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Neurological disorders, Branches of biology, Neurodegenerative disorders, Motor neuron diseases, Neurogenetic disorders, Muscular dystrophy, Myostatin, SMA, Apitegromab, SMA, Scholar Rock, APITEGROMAB, SMA, SCHOLAR ROCK

Scholar Rock plans to initiate a Phase 3 trial to further evaluate apitegromab in patients with non-ambulatory Type 2 and Type 3 SMA by the end of 2021.

Key Points: 
  • Scholar Rock plans to initiate a Phase 3 trial to further evaluate apitegromab in patients with non-ambulatory Type 2 and Type 3 SMA by the end of 2021.
  • Apitegromab is a selective inhibitor of the activation of myostatin and is an investigational product candidate for the treatment of patients with spinal muscular atrophy (SMA).
  • Scholar Rock believes that inhibiting myostatin activation with apitegromab may promote a clinically meaningful improvement in motor function in patients with SMA.
  • Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path.

Rett Syndrome Research Trust Announces Development of the ORCA Measure to Assess Communication Ability of Individuals with Rett Syndrome

Retrieved on: 
Thursday, June 17, 2021
Branches of biology, Neurological disorders, Clinical medicine, Health, Learning disabilities, Psychiatric diagnosis, Developmental neuroscience, Pervasive developmental disorders, Rett, Neurodevelopmental disorder, Angelman syndrome

"Most individuals with Rett Syndrome have great difficulties communicating, so parents and caregivers are often at a loss in understanding their loved one's needs and wants," said Monica Coenraads, Chief Executive Officer of the Rett Syndrome Research Trust (RSRT).

Key Points: 
  • "Most individuals with Rett Syndrome have great difficulties communicating, so parents and caregivers are often at a loss in understanding their loved one's needs and wants," said Monica Coenraads, Chief Executive Officer of the Rett Syndrome Research Trust (RSRT).
  • Currently, there is no comprehensive tool to assess communication among individuals with Rett Syndrome.
  • The tool was created to measure communication abilities in individuals living with Angelman Syndrome, another neurodevelopmental disorder with communication challenges similar to Rett Syndrome.
  • Scientists estimate that the Rett ORCA study will need to enroll 270 Rett Syndrome families in order to satisfy the requirements for FDA validation.

Autism Learning Partners Expands ABA Services in Utah to Salt Lake City

Retrieved on: 
Thursday, June 17, 2021
Psychiatric diagnosis, Psychiatry, Neurological disorders, Pervasive developmental disorders, Branches of biology, Abnormal psychology, Autism, Cision

SALT LAKE CITY, June 17, 2021 /PRNewswire-PRWeb/ --ALP strives to give hope, support, and paths of progress for children and their families living with autism and related disorders.

Key Points: 
  • SALT LAKE CITY, June 17, 2021 /PRNewswire-PRWeb/ --ALP strives to give hope, support, and paths of progress for children and their families living with autism and related disorders.
  • "We have been grateful to support families in Provo, Utah since June of 2019 and look forward to the expansion into Salt Lake City with the collaboration of community members, talented BCBA's and behavior technicians.
  • Services include: Applied Behavioral Analysis and additionally offer speech, occupational, physical therapies, and diagnostic services in select regions.
  • To learn more about Autism Learning Partners and its services, please visit AutismLearningPartners.com.

M&T Bank and Life-Skills App Magnusmode Collaborate to Support Customers with Autism, Cognitive and Intellectual Disabilities

Retrieved on: 
Tuesday, June 15, 2021
Psychiatry, Psychiatric diagnosis, Abnormal psychology, Learning disabilities, Branches of biology, Pervasive developmental disorders, Neurological disorders, Childhood psychiatric disorders, Autism, Disability, Dementia, Attention deficit hyperactivity disorder

"We are excited to work with Magnusmode not only because they're an inspiring local startup, but also because their product is incredibly intuitive and well-designed to support our customers."

Key Points: 
  • "We are excited to work with Magnusmode not only because they're an inspiring local startup, but also because their product is incredibly intuitive and well-designed to support our customers."
  • Using digitalized "Card Decks," the MagnusCards app guides users through tasks and activities that might otherwise feel challenging or overwhelming.
  • The app's users include people with autism, down syndrome, acquired brain injury, dementia, ADHD and other cognitive disabilities.
  • "Confusing or complex services can create barriers for people with autism and other cognitive disabilities.

Muscular Dystrophy Association Releases New PSA Campaign with Indianapolis Colts Running Back Nyheim Hines

Retrieved on: 
Tuesday, June 15, 2021
Neurological disorders, Amyotrophic lateral sclerosis, Muscular Dystrophy Association, Organ systems, Musculoskeletal disorders, Muscular dystrophy, Dystrophy, MDA, Neuromuscular disease, Muscular Dystrophy UK

Hines is a running back for the Indianapolis Colts of the National Football League (NFL).

Key Points: 
  • Hines is a running back for the Indianapolis Colts of the National Football League (NFL).
  • He has long been a supporter of MDA through the NFL's My Cause My Cleats campaign.
  • "MDA is the leading organization in advancing the community's needs and advocating for improving care and finding cures for people living with muscular dystrophy.
  • For 70 years, the Muscular Dystrophy Association (MDA) has been committed to transforming the lives of people living with muscular dystrophy, ALS, and related neuromuscular diseases.

Muscular Dystrophy Association Launches Quest Podcast Hosted By Motivational Speaker and Author Mindy Henderson

Retrieved on: 
Monday, June 14, 2021
Neurological disorders, Branches of biology, Neurodegenerative disorders, Neurogenetic disorders, Neuromuscular Disorders, Motor neuron diseases, Amyotrophic lateral sclerosis, Muscular Dystrophy Association, Neuromuscular disease, Rare diseases, Dystrophy, Muscular dystrophy

The podcast will be hosted by Mindy Henderson , who lives with neuromuscular disease and is a motivational speaker, author, and hostof " The Truth About Things That Suck " podcast.

Key Points: 
  • The podcast will be hosted by Mindy Henderson , who lives with neuromuscular disease and is a motivational speaker, author, and hostof " The Truth About Things That Suck " podcast.
  • Henderson was diagnosed with spinal muscular atrophy (SMA) when she was 15 months old.
  • "I'm thrilled to be hosting the new Quest Podcast," said Henderson.
  • For 70 years, the Muscular Dystrophy Association (MDA) has been committed to transforming the lives of people living with muscular dystrophy, ALS, and related neuromuscular diseases.

Virtis Health Expands Ambulatory Infusion Center Footprint and Infusion Management Services

Retrieved on: 
Monday, June 14, 2021
Other Health, Radiology, Pharmaceutical, Insurance, Medical devices, Infectious diseases, Hospitals, Professional services, Practice Management, Physical therapy, Nursing, Managed care, Cardiology, General Health, Biotechnology, Diabetes, Surgery, AIDS, Health, Medical specialties, Autoimmune diseases, Clinical medicine, Medicine, Neurological disorders, Chronic inflammatory demyelinating polyneuropathy, Autoimmunity, Polyneuropathy, Myasthenia gravis, Transfusion medicine

Concurrently, the Company continues to expand its comprehensive infusion management and related physician practice management services nationwide.

Key Points: 
  • Concurrently, the Company continues to expand its comprehensive infusion management and related physician practice management services nationwide.
  • Virtis Health offers a range of therapy management services and treatments for patients with autoimmune disorders, including chronic inflammatory demyelinating polyneuropathy (CIDP), multiple sclerosis and myasthenia gravis.
  • Virtis Healths Physician Services division provides comprehensive infusion center and practice management services to support physician and provider partners.
  • Additionally, the Company provides comprehensive infusion center and related practice management services to physicians, health systems and other medical entities nationwide.

Cognito Therapeutics Initiates Studies in Down Syndrome Associated Alzheimer’s Disease

Retrieved on: 
Monday, June 14, 2021
Health, Other Science, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Branches of biology, Biology, Learning disabilities, Psychiatric diagnosis, Neurological disorders, Neuroscience, Alzheimer's disease, Dementia, Neurodegeneration

Cognito Therapeutics , a clinical-stage company leading the development of a new class of disease-modifying digital therapeutics to treat neurodegenerative disorders including Alzheimers disease, announced today its plans to add a second digital therapeutic to the companys pipeline, initiating a new study evaluating digital therapeutic for individuals who have the genetic rare disease, Down syndrome associated Alzheimers Disease (DS-AD).

Key Points: 
  • Cognito Therapeutics , a clinical-stage company leading the development of a new class of disease-modifying digital therapeutics to treat neurodegenerative disorders including Alzheimers disease, announced today its plans to add a second digital therapeutic to the companys pipeline, initiating a new study evaluating digital therapeutic for individuals who have the genetic rare disease, Down syndrome associated Alzheimers Disease (DS-AD).
  • Roughly half of the participants with Down syndrome indicated having symptoms of cognitive decline associated with Alzheimers disease or had a confirmed diagnosis.
  • Down Syndrome associated Alzheimers Disease is a genetically associated, aggressive form of Alzheimers where individuals with Down syndrome are born with an extra copy of chromosome 21, which carries a gene that produces a specific protein called amyloid precursor protein (APP).
  • Cognito Therapeutics is a clinical-stage company developing a pipeline of disease-modifying digital therapeutics that have shown drug-like effects to treat neurodegenerative disorders including Alzheimers disease.